Tharimmune Inc. (THAR)
1.42
-0.01 (-0.70%)
At close: Mar 03, 2025, 3:59 PM
1.36
-4.23%
After-hours: Mar 03, 2025, 05:01 PM EST
No 1D chart data available
| Bid | 1.36 |
| Market Cap | 2.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.42M |
| EPS (ttm) | 61.01 |
| PE Ratio (ttm) | 0.02 |
| Forward PE | -16.5 |
| Analyst | Buy |
| Ask | 1.71 |
| Volume | 71,305 |
| Avg. Volume (20D) | 94,508 |
| Open | 1.45 |
| Previous Close | 1.43 |
| Day's Range | 1.39 - 1.46 |
| 52-Week Range | 1.36 - 7.46 |
| Beta | 1.27 |
About THAR
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed c...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 12, 2022
Employees 2
Stock Exchange NASDAQ
Ticker Symbol THAR
Website https://www.tharimmune.com
Analyst Forecast
According to 1 analyst ratings, the average rating for THAR stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 1097.18% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 months ago
+10.84%
Tharimmune shares are trading higher after it anno...
Unlock content with
Pro Subscription
4 months ago
+68.97%
Tharimmune shares are trading higher after the company announced it received EMA feedback on its TH104 clinical program. The design and main features of the proposed Phase 2 study were deemed acceptable and general guidance was also provided for a future Phase 3 study.
